2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited States
2022
Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases 2022, 76: e350-e359. PMID: 35717642, PMCID: PMC9214178, DOI: 10.1093/cid/ciac438.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Immunological exposureOmicron variantSevere diseaseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionFuture SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsUS populationSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionPopulation-level immunityPrior immunological exposurePopulation immunityImmune escapeVaccination dataInfectionInfection statusVaccinationUS statesEffective protectionDiseaseImmunity
2016
Identifying cost‐effective dynamic policies to control epidemics
Yaesoubi R, Cohen T. Identifying cost‐effective dynamic policies to control epidemics. Statistics In Medicine 2016, 35: 5189-5209. PMID: 27449759, PMCID: PMC5096998, DOI: 10.1002/sim.7047.Peer-Reviewed Original ResearchConceptsNet health benefitHighest net health benefitHealth benefitsTransmission-reducing interventionsDynamic policiesNovel viral pathogensCurrent interventionsHealth policyMathematical decision modelViral pathogensMonetary outcomesPolicy makersInterventionPolicyDecision modelStatic policyEpidemicEpidemic dataVaccinationVaccinePerformance measures
2008
Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines
Cohen T, Colijn C, Murray M. Modeling the effects of strain diversity and mechanisms of strain competition on the potential performance of new tuberculosis vaccines. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 16302-16307. PMID: 18849476, PMCID: PMC2570977, DOI: 10.1073/pnas.0808746105.Peer-Reviewed Original ResearchConceptsNew tuberculosis vaccinesTuberculosis vaccineBacillus Calmette-Guérin (BCG) vaccinationCurrent vaccine candidatesM. tuberculosis strainsPerformance of vaccinesTuberculosis infectionTuberculosis controlStrain diversityMass vaccinationVaccine candidatesNew vaccinesTuberculosis strainsStrain replacementVaccineM. tuberculosisMycobacterium tuberculosisTransmission of diseaseVaccinationTuberculosisInfectionDiseaseStrain specificityPotential effectsMorbidity